Can GLP-1 Medications Help With Alcohol Use Disorder?
Real, published clinical evidence suggests semaglutide may help reduce drinking and alcohol cravings in people with alcohol use disorder, but this is not yet an FDA-approved use.
The Real Evidence So Far
A randomized, placebo-controlled trial published in The Lancet in May 2026 found that semaglutide combined with cognitive behavioral therapy significantly reduced heavy drinking days. A separate phase 2 trial published in JAMA Psychiatry found low-dose semaglutide reduced both alcohol consumption and craving.
A Real, Current Nationwide Trial
The U.S. Department of Veterans Affairs launched a nationwide clinical trial specifically studying semaglutide for alcohol use disorder, with recruitment opening July 28, 2026.
An Important Caution
The VA has explicitly stated it strongly discourages self-medicating or attempting to replace established alcohol use disorder treatments with GLP-1 medications. This research is genuinely promising, but not yet a substitute for established care.
Related Reading
For the full GLP-1 knowledge base, explore DietApp's GLP-1 Tracker hub
Comments